PIII Quote, Financials, Valuation and Earnings

Astrana Health has a net margin of -12.84% compared to P3 Health Partners's net margin of -1.05%. P3 Health Partners's return on equity of -26.35% beat Astrana Health's return on equity of 9.13%.

P3 Health Partners has a consensus price target of $0.63, signalling upside risk potential of 268.3%. On the other hand Astrana Health has an analysts' consensus of $52.3000 which suggests that it could grow by 79.14%. Given that P3 Health Partners has higher upside potential than Astrana Health, analysts believe P3 Health Partners is more attractive than Astrana Health.

P3 Health Partners has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Astrana Health has a beta of 1.297, suggesting its more volatile than the S&P 500 by 29.713%.

P3 Health Partners has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Astrana Health offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. P3 Health Partners pays -- of its earnings as a dividend. Astrana Health pays out -- of its earnings as a dividend.

P3 Health Partners quarterly revenues are $362.1M, which are smaller than Astrana Health quarterly revenues of $665.2M. P3 Health Partners's net income of -$46.5M is lower than Astrana Health's net income of -$7M. Notably, P3 Health Partners's price-to-earnings ratio is -- while Astrana Health's PE ratio is 32.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for P3 Health Partners is 0.02x versus 0.68x for Astrana Health. Usually stocks with elevated PS ratios are considered overvalued.

Biote has a net margin of -12.84% compared to P3 Health Partners's net margin of 7.43%. P3 Health Partners's return on equity of -26.35% beat Biote's return on equity of --.

P3 Health Partners has a consensus price target of $0.63, signalling upside risk potential of 268.3%. On the other hand Biote has an analysts' consensus of $8.21 which suggests that it could grow by 167.32%. Given that P3 Health Partners has higher upside potential than Biote, analysts believe P3 Health Partners is more attractive than Biote.

P3 Health Partners has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Biote has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

P3 Health Partners has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biote offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. P3 Health Partners pays -- of its earnings as a dividend. Biote pays out 150.27% of its earnings as a dividend.

P3 Health Partners quarterly revenues are $362.1M, which are larger than Biote quarterly revenues of $49.8M. P3 Health Partners's net income of -$46.5M is lower than Biote's net income of $3.7M. Notably, P3 Health Partners's price-to-earnings ratio is -- while Biote's PE ratio is 17.06x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for P3 Health Partners is 0.02x versus 0.53x for Biote. Usually stocks with elevated PS ratios are considered overvalued.

Cryo-Cell International has a net margin of -12.84% compared to P3 Health Partners's net margin of 13.04%. P3 Health Partners's return on equity of -26.35% beat Cryo-Cell International's return on equity of --.

P3 Health Partners has a consensus price target of $0.63, signalling upside risk potential of 268.3%. On the other hand Cryo-Cell International has an analysts' consensus of $8.50 which suggests that it could grow by 31.01%. Given that P3 Health Partners has higher upside potential than Cryo-Cell International, analysts believe P3 Health Partners is more attractive than Cryo-Cell International.

P3 Health Partners has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Cryo-Cell International has a beta of 0.570, suggesting its less volatile than the S&P 500 by 42.967%.

P3 Health Partners has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cryo-Cell International offers a yield of 7.71% to investors and pays a quarterly dividend of $0.25 per share. P3 Health Partners pays -- of its earnings as a dividend. Cryo-Cell International pays out 502.5% of its earnings as a dividend.

P3 Health Partners quarterly revenues are $362.1M, which are larger than Cryo-Cell International quarterly revenues of $8.1M. P3 Health Partners's net income of -$46.5M is lower than Cryo-Cell International's net income of $1.1M. Notably, P3 Health Partners's price-to-earnings ratio is -- while Cryo-Cell International's PE ratio is 136.93x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for P3 Health Partners is 0.02x versus 1.66x for Cryo-Cell International. Usually stocks with elevated PS ratios are considered overvalued.

Omnicell has a net margin of -12.84% compared to P3 Health Partners's net margin of 5.16%. P3 Health Partners's return on equity of -26.35% beat Omnicell's return on equity of 1.04%.

P3 Health Partners has a consensus price target of $0.63, signalling upside risk potential of 268.3%. On the other hand Omnicell has an analysts' consensus of $52.14 which suggests that it could grow by 61.53%. Given that P3 Health Partners has higher upside potential than Omnicell, analysts believe P3 Health Partners is more attractive than Omnicell.

P3 Health Partners has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Omnicell has a beta of 0.849, suggesting its less volatile than the S&P 500 by 15.083%.

P3 Health Partners has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Omnicell offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. P3 Health Partners pays -- of its earnings as a dividend. Omnicell pays out -- of its earnings as a dividend.

P3 Health Partners quarterly revenues are $362.1M, which are larger than Omnicell quarterly revenues of $306.9M. P3 Health Partners's net income of -$46.5M is lower than Omnicell's net income of $15.8M. Notably, P3 Health Partners's price-to-earnings ratio is -- while Omnicell's PE ratio is 119.56x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for P3 Health Partners is 0.02x versus 1.35x for Omnicell. Usually stocks with elevated PS ratios are considered overvalued.